Trevi Therapeutics, Inc.
Trevi Therapeutics, Inc. is a company.
Active
Updated: ·
Financial History
Total Raised
N/A
Valuation
N/A
Leadership Team
Key people at Trevi Therapeutics, Inc..
Trevi Therapeutics, Inc. is a company.
Key people at Trevi Therapeutics, Inc..
Key people at Trevi Therapeutics, Inc..
Trevi Therapeutics, Inc. (NASDAQ: TRVI) is a clinical-stage biopharmaceutical company dedicated to developing Haduvio™ (oral nalbuphine ER), its sole investigational therapy, to treat chronic cough in patients with idiopathic pulmonary fibrosis (IPF), refractory chronic cough (RCC), and potentially non-IPF interstitial lung disease (ILD).[1][2][3][6] Haduvio targets the cough reflex arc centrally and peripherally as a kappa opioid agonist and mu antagonist (KAMA), addressing unmet needs in conditions with no approved U.S. therapies, serving patients whose quality of life is severely impacted by debilitating, untreatable cough.[1][3][6] The company demonstrated growth momentum in 2025 with positive Phase 2b CORAL trial results in IPF chronic cough and Phase 2a RIVER trial in RCC, showing statistically significant cough frequency reductions—the first such outcomes in these indications—while maintaining capital efficiency with Q3 2025 net loss of $11.8 million and R&D expenses of $10.1 million.[1][6]
Founded between 2011 and 2015, Trevi Therapeutics emerged from New Haven, Connecticut's burgeoning biotech ecosystem, leveraging local universities, industry collaborators like Alexion AstraZeneca and Pfizer, and a patient-centric focus on chronic cough hypersensitivity.[2][3][4][5] Under President and CEO Jennifer Good, the company honed its idea around Haduvio's novel mechanism targeting opioid receptors in the cough reflex arc, advancing it through clinical stages amid a fast-paced, entrepreneurial environment.[3][4][6] Early traction built through disciplined R&D, culminating in 2025's pivotal Phase 2 trial successes in IPF and RCC, positioning Trevi as a leader in specialty respiratory indications.[1][6]
Trevi rides the wave of precision neurology and respiratory therapies, targeting cough hypersensitivity—a hypersensitive neural disorder in chronic conditions like IPF and RCC amid rising interstitial lung disease prevalence and post-pandemic cough awareness.[2][6] Timing aligns with no U.S.-approved treatments, creating first-mover advantage in a market burdened by patient, caregiver, and system costs, bolstered by positive 2025 trial data and New Haven's life-sciences growth.[1][3][5][6] Trevi influences the ecosystem by pioneering KAMA modulation, potentially expanding to pruritus and inspiring biomarker-driven biotech in underserved cardiorespiratory spaces.[2]
Trevi's next catalysts include topline Phase 2b IPF data (already positive from 2025) and potential Phase 3 advancement for Haduvio, with earnings on March 17, 2026, amid a negative P/E of -38.41 signaling pre-revenue growth stage.[2][3] Trends like precision medicine, oral therapies for chronic conditions, and biotech efficiency will shape its path, evolving Trevi from clinical player to commercial leader in cough therapeutics. As the sole focused developer delivering breakthrough cough reductions, Trevi stands poised to transform untreatable suffering into manageable care.[1][6]
